We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0CUM market cap is 2.17T. The company's latest EPS is DKK -0.7377 and P/E is -122.00.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Revenue | 0 | 0 | 36.19M | 17.87M | 0 |
| Operating Income | -335.95M | -608.53M | -633.3M | -119.55M | -27.04M |
| Net Income | -337.5M | -633.25M | -626.54M | 26.07M | -26.05M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Assets | 180.75M | 822.49M | 173.23M | 58.12M | 19.31M |
| Total Liabilities | 127.79M | 201.97M | 163.89M | 16.46M | 5.07M |
| Total Equity | 52.97M | 620.53M | 9.34M | 41.67M | 14.24M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Operating | -326.82M | -539.08M | -602.57M | -117.95M | -20.02M |
| Investing | -3.29M | -5.1M | 46k | 90.35M | -6.94M |
| Financing | 58.94M | 1.16B | -30.34M | -35.08M | -685k |
| Market Cap | 2.17T |
| Price to Earnings Ratio | -122.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 282.04 |
| Price to Book Ratio | 223.15 |
| Dividend Yield | - |
| Shares Outstanding | 35.31M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 61,590.00 |
| 52 Week Low | 61,590.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Orphazyme A/s |
| Address |
ole maal��es vej 3 copenhagen DK-2200 |
| Website | https://www.orphazyme.com |
| Industry | med, dental, hosp eq-whsl (5047) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
